Kineto Forte

Serrapeptase

Method of action: Other Drugs For Disorders Of The Musculo-Skeletal System

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kineto Forte

Property	Description
Active ingredient	Serrapeptase (Serratiopeptidase)
Form	Enteric-coated tablet (or capsule)
Pharmacological class	Proteolytic enzyme, Systemic enzyme
General purpose	Support for inflammation and swelling reduction
Origin	Biologically-derived (from Serratia marcescens)

What Type of Medicine is Kineto Forte?

Kineto Forte is an oral systemic enzymatic agent defined by its single active ingredient, the potent proteolytic enzyme Serrapeptase, also identified as Serratiopeptidase. This preparation is classified pharmacologically as a systemic enzyme and an anti-inflammatory enzyme. Unlike typical chemical anti-inflammatory drugs, Serrapeptase is biologically-derived, originating from the Serratia marcescens bacterial species. Its pharmacological action has been clinically recognized for its systemic role in supportive therapy for inflammatory conditions.

Composition and How the Tablet is Formulated

The medicine is supplied for oral administration as a single-ingredient product, most often formulated as an enteric-coated tablet. This specialized enteric coating is a critical component necessary to protect the enzyme from being destroyed by the strong acidity of the stomach. The coating ensures that the fragile Serrapeptase enzyme remains intact until it reaches the small intestine, where it is absorbed to initiate its systemic activity. This specific dosage form is essential for achieving effective systemic delivery.

What is the General Therapeutic Purpose of Serrapeptase?

The general function of Serrapeptase is to leverage its proteolytic capability to support the body’s natural process for managing discomfort associated with inflammation. Its key physiological action is selective proteolysis, which involves breaking down specific non-living protein compounds, such as accumulated fibrin and certain debris. By assisting with the clearance of protein waste, this enzyme exhibits an anti-edemic effect, which generally helps to reduce swelling and relieve associated symptoms like stiffness and tension caused by inflammatory responses.

What side effects are possible with Kineto Forte?

Possible Side Effects and Safety Information

The information in this section is derived strictly from government regulatory sources and official health product documents. Safety classifications may vary by region; the terminology used is based on official label information.

Officially Documented Adverse Reactions

The most commonly listed adverse reactions for Serrapeptase (the active ingredient in Kineto Forte) generally affect the digestive system and skin. Many of these effects are listed with a Frequency not defined classification in regulatory summaries.

System-Organ Class	Examples of Listed Effects
Gastrointestinal Disorders	Gastric discomfort, Diarrhoea, Vomiting, Anorexia (loss of appetite)
Skin and Subcutaneous Tissue	Skin rash, Hypersensitivity (Allergic reactions)
Respiratory Disorders	Epistaxis (nosebleed), Cough

Serious Safety Concerns and Restrictions

Official labeling highlights the potential for serious adverse reactions and conditions that require specific caution:

Risk of Bleeding: Due to its activity, the medicine may increase the risk of bruising and bleeding and may worsen existing bleeding disorders. It is officially advised to stop use at least two weeks before any scheduled surgical procedures.
Hypersensitivity: The medicine carries a risk of severe allergy. Regulatory documents instruct to stop use if rash, difficulty breathing, or severe allergy occur.
Peptic Ulcer Disease: Use may aggravate symptoms in individuals with active peptic ulcer disease.

Population-Specific Safety Statements

Official safety profiles indicate a lack of established data for certain groups:

Pregnancy and Breastfeeding: Safety during these periods has not been established, and caution is advised.
Duration of Use: The long-term safety of the medicine (use beyond four weeks) is not known.
Hepatic/Renal Impairment: Caution is advised for individuals with impaired liver or kidney function.

Overdose and Emergency Response

The official regulatory profile for Kineto Forte overdose is based on documented risks of severe adverse reactions resulting from excessive intake of the active ingredient, Serrapeptase.

Documented Overdose Manifestations

Overdose manifestations may present as an exaggeration of known systemic effects. These include severe gastrointestinal distress, encompassing pronounced nausea, vomiting, and diarrhea. Given the enzyme's systemic properties, a critical potential outcome is a severe blood clotting disturbance, which can manifest as unusual bleeding or bruising. The appearance of significant skin rashes or other signs of hypersensitivity also constitutes a serious, documented event.

When Immediate Medical Help Is Required

Regulatory guidance mandates that immediate medical attention is required for the occurrence of any severe side effects or in any case where an overdose is suspected. Use must be stopped immediately if signs of a severe allergic reaction, such as difficulty breathing or pronounced swelling, are observed. Management of overdose is focused on symptomatic and supportive treatment, as no specific pharmacological antidote is documented in official prescribing information. A critical population note is that individuals taking anticoagulant or antiplatelet medications face a heightened risk of serious bleeding events if excessive amounts are consumed.

Therapeutic Uses of Kineto Forte

What Kineto Forte Treats: Main Uses and Benefits

Kineto Forte is commonly used in clinical settings that involve acute or unstable symptom patterns, and is generally used to help with the management of symptoms related to inflammatory or irritative states and localized swelling (oedema). Its application is relevant in contexts involving heightened systemic burden, such as post-traumatic events or specific medical procedures. Active ingredient application is generally used when appropriate to assist with the management of postoperative cheek swelling and discomfort after dental surgery.

The medicine is relevant for easing symptoms related to tissue stiffness, inflammatory or irritative states like certain forms of arthritis, and viscous mucus build-up common in conditions like chronic sinusitis and bronchitis. This supportive relief helps address symptom clusters that interfere with daily functioning and contributes to easing the overall symptom load.

“The focus of this medicine is to provide symptomatic relief; it is applied when additional management of discomfort is required to support patient comfort during difficult episodes.”

Quick Fact: Relevant for Swelling and Viscous Mucus Symptoms

Regulatory References

Health Canada Natural Health Product Monograph

Eligibility and Restrictions for Use

Who Can and Cannot Use Kineto Forte? — Official Eligibility Information

Kineto Forte is for use by the general adult population, excluding individuals with specific conditions or clinical states outlined in regulatory documentation. Eligibility is strictly defined by contraindications and special warnings.

Populations for Whom Use is Prohibited (Contraindicated)

Use of Kineto Forte is formally contraindicated in patients with the following conditions:

Known hypersensitivity or allergy to the medicine or its ingredients.
A history of bleeding disorders or other conditions posing a high risk of bleeding (e.g., suspected cerebrovascular bleeding).
Severe kidney failure (including patients undergoing dialysis) or advanced renal impairment.
Severe liver problems or active peptic ulcer disease, recent gastrointestinal bleeding, or perforation.
For the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

Groups with Restricted or Not Recommended Use

The medicine is generally not recommended or requires special consideration for:

Children (pediatric use): Safety and effectiveness have not been established.
Pregnancy and Lactation: Use during pregnancy (especially the third trimester) and while breastfeeding is not recommended due to unestablished safety.
Elderly Patients: May be at greater risk for serious gastrointestinal events and may require dosage adjustment due to age-related kidney function changes.
Patients taking aspirin or other NSAIDs concurrently, due to increased risk of serious adverse effects.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The regulatory profile for Kineto Forte (Serrapeptase) is defined primarily by its pharmacodynamic interaction with co-administered substances that affect blood coagulation. The core interaction documented in official health product monographs involves medicinal products that slow clotting.

Pharmacodynamic Interaction Profile

The medicine may produce an additive anti-clotting effect when combined with anticoagulant agents (such as Warfarin or Heparin) and antiplatelet agents (including Aspirin, Clopidogrel, and certain NSAIDs). This combination is officially stated to increase the risk of bleeding and bruising. This is classified as a clinically significant interaction that necessitates a restriction on co-administration.

Timing and Substance Restrictions

Official documents impose a crucial time-based restriction related to this interaction risk. The product must be discontinued at least two weeks prior to any scheduled surgical or dental procedure to minimize the potential for excessive bleeding. Furthermore, the risk of bleeding may also be increased with the co-administration of alcohol or certain herbal products and supplements (e.g., Garlic, Fish Oil, Turmeric) recognized for their anti-clotting properties. No specific metabolic (CYP) or transporter-mediated pharmacokinetic interactions are documented in official regulatory materials.

Mechanism of Action

Enzymatic Breakdown of Inflammatory Proteins

Kineto Forte functions as a proteolytic enzyme that directly targets and hydrolyzes (breaks down) non-viable proteins and excessive inflammatory mediators, such as fibrin and certain kinins, within the tissue. This key molecular action clears protein debris and lowers the concentration of specific protein mediators in the inflammatory cascade.

Influencing Fluid Dynamics and Exudate Clearance

By degrading high-molecular-weight proteins in the affected area, the drug's mechanism effectively lowers the viscosity and oncotic pressure of the accumulated fluid (exudate). This facilitates fluid reabsorption and lymphatic drainage, resulting in decreased fluid accumulation and protein concentration in the extracellular space.

Influence on Tissue Pressure and Sensory Nerve Signaling

The resolution of increased localized pressure and the decrease in inflammatory protein mediators modify the signaling environment near peripheral sensory nerve endings. This reduction of localized tension is a downstream mechanical consequence of protein and fluid clearance, which results in the overall modulation of local tissue response.

Dosage and Administration Information

How to use Kineto Forte: Administration Guidelines

This section describes the high-level administration principles for Kineto Forte (Serrapeptase), focusing strictly on standardized use, dosing, and timing.

Administration Scope

Entity	Description
Route of administration	Oral administration.
Dosing schedule	The adult unit dose is generally 10 mg of Serrapeptase, taken up to three times daily (TID). The maximum daily intake is restricted to 120,000 Serrapeptase Units (SU) (approximately 60 mg).
Timing in relation to meals	Must be taken on an empty stomach to ensure proper absorption. This requires administration 30 minutes before a meal or approximately two hours after a meal.
Preparation requirements	None. The tablet is designed for use as supplied.
Age-group administration rules	Dosing guidelines are established solely for adults 18 years and older.
Missed-dose rules	Specific, high-level missed-dose instructions are not consistently documented.
Special procedural conditions	Use is limited to short-term courses, generally requiring consultation if continued beyond seven days or four weeks, depending on the clinical context.

Instruction Classifications (High-Level)

Classification	Value
Administration method type	Oral (enteric-coated tablet).
Frequency pattern	Three times daily (TID).
Use-context constraints	Must be taken away from food and limited to short-term courses with a defined maximum daily dose.

Resulting Procedural Structure

Step sequence:

Take the prescribed unit dose of Serrapeptase by mouth.
Swallow the enteric-coated tablet whole with water. It must not be crushed, chewed, or broken, as this would compromise the enzyme’s delivery.
Administer the dose three times daily as scheduled.
Ensure the administration occurs when the stomach is empty (30 minutes prior to or two hours following a meal).
Adhere to the prescribed short-term duration and the maximum daily dose of 60 mg.

Connection to the overall use protocol The instructions establish a precise protocol centered on the oral administration of a specialized enteric-coated form. This structure mandates a fixed three-times-daily frequency alongside a crucial empty-stomach timing requirement to ensure the dosage unit passes through the gastric environment intact, adhering strictly to the standardized constraints.

Recent Clinical Evidence

Evidence for Swelling and Oedema Studies

Research has primarily focused on studies exploring the use of Serrapeptase in contexts involving post-procedural swelling (oedema) and swelling associated with trauma. This research has often utilized short-term Randomized Controlled Trials (RCTs) to compare the substance against a placebo. Investigators in these trials specifically measured outcomes related to localized swelling and changes in outcomes related to physical discomfort, often involving adult patients recovering from minor surgeries or individuals who experienced acute, localized soft tissue trauma. Findings describe patterns observed during the study periods. Trials sometimes reported measurements related to a change in swelling. However, evidence quality varies across studies, and reported outcomes related to pain intensity were often mixed or not consistently different from comparison groups. Systematic reviews indicate the overall consistency of available data for this indication is limited and heterogeneous.

Evidence for Mucus and Airway Studies

Research examined the use of the enzyme Serrapeptase in conditions involving viscous mucus, such as those related to chronic sinusitis and chronic bronchitis. This research included controlled clinical trials that focused on changes in the physical characteristics of airway secretions. Studies explored outcomes related to sputum characteristics, tracking changes in their thickness and elasticity. Findings indicate that changes in the viscosity of airway secretions were observed in some studies. Overall, the available evidence is limited, and there is no broad consensus from authoritative systematic reviews regarding the full clinical significance of the reported short-term changes.

Long-Term Studies and Follow-Up Duration

Studies exploring Serrapeptase are relevant in trials assessing short-term or episodic symptom patterns and are typically of short follow-up duration, ranging from only a few days to a few weeks. This means that while existing evidence provides insight into short-term changes observed during the study period, long-term effects are not fully established. The research does not determine whether an individual will respond similarly over extended periods.

Evidence in Special Populations

The populations included in the primary research exploring Serrapeptase were generally limited to adults in the clinical trials. Data for certain groups remain insufficient. There is a notable lack of comprehensive, dedicated research examining the use of the enzyme in children or older adults.

What the Research Landscape Shows About Consistency and Limitations

The overall certainty surrounding the evidence remains low, largely due to methodological weaknesses and small sample sizes in many individual trials. Evidence quality varies across studies, and results are often mixed when comparing the substance to established treatments. Research is ongoing to better contextualize the enzyme within the broader evidence landscape.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Kineto Forte (FAQ)

Q: What is Kineto Forte and how does it work?

The active ingredient in Kineto Forte is believed to interact with specific enzymes or receptors involved in cellular energy regulation and neurogenesis. It is primarily studied for its potential effects on mitochondrial function, which is critical for cellular health and energy production, particularly in muscle and nerve tissues. This action is hypothesized to support cellular repair and reduce oxidative stress, contributing to its overall therapeutic profile.

Q: What is Kineto Forte typically used to treat?

Kineto Forte is often used as a supplementary treatment for conditions characterized by chronic fatigue, muscle weakness, or age-related cognitive decline. It may be recommended to support the management of certain rare disorders where mitochondrial dysfunction is a primary factor. Its use is based on its proposed role in supporting energy metabolism, particularly in high-energy-demand organs like the brain and skeletal muscles.

Q: What are the common side effects of Kineto Forte?

Commonly reported side effects of Kineto Forte are generally mild and temporary. These can include:

Gastrointestinal issues, such as mild nausea, diarrhea, or stomach discomfort.
Headache.
Dizziness.

If these effects persist or worsen, it is important to consult a healthcare professional.

Q: Can Kineto Forte be taken with other medications?

It is crucial to discuss all current medications, supplements, and herbal products with a healthcare provider before starting Kineto Forte. Potential interactions have been noted, particularly with medications that affect blood clotting or central nervous system activity. A healthcare professional can assess the risk of interaction and determine if Kineto Forte is safe to use alongside other treatments.

Q: How long does it take for Kineto Forte to start working?

The time it takes for Kineto Forte to produce noticeable effects can vary significantly among individuals. While some patients report improvements within a few weeks, others may require several months of consistent use to experience its full therapeutic benefit. Because its action is related to supporting underlying cellular processes, results are often gradual. Adherence to the prescribed regimen is key for assessing its efficacy.

Q: Is Kineto Forte safe for long-term use?

Clinical data regarding the long-term safety of Kineto Forte is generally positive, especially when used under the supervision of a healthcare professional. Studies support its tolerability over extended periods. Regular monitoring and follow-up appointments are recommended to ensure continued safety and to adjust the treatment plan as needed. Any concerns about long-term effects should be directed to a physician.

Q: Are there any lifestyle changes recommended while taking Kineto Forte?

While Kineto Forte is used to support energy and cellular health, it is often most effective when combined with healthy lifestyle practices. Patients are typically encouraged to maintain a balanced diet, engage in regular, moderate exercise (as tolerated), and prioritize adequate sleep. These habits complement the medication's intended effects by supporting overall metabolic and physical wellness.

How should Kineto Forte be stored and disposed of?

The official regulatory information dictates specific environmental and safety rules for Kineto Forte (serratiopeptidase) to maintain the product's integrity.

Storage and Disposal Requirement	Details
Temperature	Store in a cool, dry place, typically at or below 30°C.
Protection	Keep in the original container, tightly closed, and protect from light and moisture.
Child Safety	The medicine must be stored out of the sight and reach of children.
Disposal	Disposal should follow established regulatory guidelines for non-hazardous medicines. This means prioritizing drug take-back programs or mixing with an undesirable substance (e.g., dirt) and sealing the mixture for safe household trash disposal. Do not flush unless the label explicitly permits it.